Methods and composition for cell-based therapy as well as somatostatin receptor-based therapy are described. For example, in certain aspects methods for administering an anti-tumor therapy using a signaling defective somatostatin receptor mutant are described. Furthermore, the invention provides compositions and methods involve a somatostatin constitutively active somatostatin receptor mutant.

The present invention provides a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand and the ion of an alpha-emitting thorium radionuclide. The invention additionally provides therapeutic methods employing such complexes, methods of their production and use, and kits and pharmaceutical compositions comprising such complexes.

The present invention comprises a method for the generation of .sup.227Th of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising .sup.227Ac, .sup.227Th and .sup.223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting a mixture of said .sup.223Ra and .sup.227Ac from said strong base anion exchange resin using a first mineral acid in an aqueous solution; iv) eluting .sup.227Th from said strong base anion exchange resin using a second mineral acid in an aqueous solution whereby to generate a first .sup.227Th solution containing contaminant .sup.223Ra and .sup.227Ac; v) loading the first .sup.227Th solution onto a strong acid cation exchange resin; vi) eluting at least a part of the contaminant .sup.223Ra and .sup.227Ac from said strong acid cation exchange resin using a third mineral acid in aqueous solution; and vii) eluting the .sup.227Th from said strong acid cation exchange resin using a first aqueous buffer solution to provide a second .sup.227Th solution. Purified thorium-227 of pharmaceutical purity and a pharmaceutical composition comprising the same are also provided.

The present invention comprises a method for the generation of .sup.227Th of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising .sup.227Ac, .sup.227Th and .sup.223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting a mixture of said .sup.223Ra and .sup.227Ac from said strong base anion exchange resin using a first mineral acid in an aqueous solution; iv) eluting .sup.227Th from said strong base anion exchange resin using a second mineral acid in an aqueous solution whereby to generate a first .sup.227Th solution containing contaminant .sup.223Ra and .sup.227Ac; v) loading the first .sup.227Th solution onto a strong acid cation exchange resin; vi) eluting at least a part of the contaminant .sup.223Ra and .sup.227Ac from said strong acid cation exchange resin using a third mineral acid in aqueous solution; and vii) eluting the .sup.227Th from said strong acid cation exchange resin using a first aqueous buffer solution to provide a second .sup.227Th solution. Purified thorium-227 of pharmaceutical purity and a pharmaceutical composition comprising the same are also provided.

Provided herein, inter alia, are nucleic acid compounds capable of binding transferrin receptor on a cell and internalizing into said cell. The compositions provided herein may be useful for delivering therapeutic and diagnostic agents to a cell. Further provided are pharmaceutical compositions and methods of treatment using nucleic acid compounds provided herein.

A method of delivering a radioactive liquid includes, performing an initialization, including; extracting at least a first amount of a radioactive liquid from a source of radioactive liquid, measuring a radioactivity level for the first amount of radioactive liquid, and performing a calibration phase. The calibration phase includes, extracting a second amount of radioactive liquid from the source of radioactive liquid wherein the second amount is calculated based on the radioactivity level of the first amount to provide a total dose of radioactive liquid having a predetermined radioactivity level, and delivering the total dose and performing at least one more calibration and delivery phases.

A method of delivering a radioactive liquid includes, performing an initialization, including; extracting at least a first amount of a radioactive liquid from a source of radioactive liquid, measuring a radioactivity level for the first amount of radioactive liquid, and performing a calibration phase. The calibration phase includes, extracting a second amount of radioactive liquid from the source of radioactive liquid wherein the second amount is calculated based on the radioactivity level of the first amount to provide a total dose of radioactive liquid having a predetermined radioactivity level, and delivering the total dose and performing at least one more calibration and delivery phases.

The present invention relates to a CT contrast agent for detecting a thrombus, comprising fibrin-targeted peptide sequence-conjugated glycol chitosan-gold nanoparticles. The CT contrast agent for detecting a thrombus according to an embodiment of the present invention may allow rapid and repeated acquisition of CT image information related to the size and location of a thrombus in cardio-cerebral vascular thrombosis, and also enables the imaging monitoring of cerebral thrombus.

The invention relates to a kit for preparation of target radiopharmaceuticals, a method of using the kit to prepare target radiopharmaceuticals and use of the target radiopharmaceuticals. The target radiopharmaceuticals comprise a radio-nuclear loading on liposome and inhibit the tumor growth and metastatic progression of head and neck cancer, lung cancer and brain cancer. The radiopharmaceuticals may be used for treating the mentioned cancers.

Preferred embodiments relate to compositions of inherently radiopaque, biocompatible, bioresorbable polymeric particles and methods of using them for embolizing a body lumen.